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Hepatocellular carcinomaTransforming growth factor-β1 (TGF-β1) induces apoptosis in normal hepatocytes and hepatoma cells. PDCD4 is
involved in TGF-β1-induced apoptosis via the Smad pathway. The tumor promoter 12-O-tetradecanoylphorbor-
13-acetate (TPA), a protein kinase C stimulator, inhibits TGF-β1-induced apoptosis. However, themechanisms of
TPA action on PDCD4 expression remain to be elucidated. Therefore. the regulatory mechanism of PDCD4
expression by PKC was investigated. The treatment of the human hepatoma cell line, Huh7 with TPA suppressed
PDCD4 protein expression and TGF-β1 failed to increase the PDCD4 protein expression. PKC inhibitors Ro-31-
8425 or bisindolylmaleimide-1-hydrocholoride (pan-PKC inhibitors) and rottlerin (PKCδ inhibitor), but not
Go6976 (PKCα inhibitor), enhanced the induction of PDCD4 protein by TGF-β1. Furthermore, siRNA-mediated
knockdownof PKCδ and ε, but not PKCα, augmented theTGF-β1-stimulatedPDCD4proteinexpression.However,
TPA or pan-PKC inhibitor did not alter the PDCD4 mRNA expression either under basal- and TGF-β1-treated
conditions. The down-regulation of PDCD4 by TPA was restored by treatment with the proteasome inhibitor
MG132. These data suggest that two isoforms of PKCs are involved in the regulation of the PDCD4 protein
expression related to the proteasomal degradation pathway.dicine, Health Administration
eshima, Saga 849-8501, Japan.
.
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The programmed cell death 4 (PDCD4) gene shows an increased
expression when apoptosis is induced. It was ﬁrst reported as MA3, a
gene associated with apoptosis in mice [1]. It was also identiﬁed as a
gene whose expression is inhibited by topoisomerase inhibitor [2], as
well as a gene involved in the cell cycle in human [3,4], and the gene
was mapped at 10q24 [5]. The overexpression of this gene in cancer
cells has been demonstrated to induce apoptosis [6]. Azzoni et al. [7]
reported the expression of this gene to be regulated by interleukins.
Subsequently, it has similarly been identiﬁed as a cancer-related gene
in chickens [8,9] and rats [10]. In addition, this gene has also been
reported to inhibit skin carcinogenesis and is thought to be a tumor
suppressor [11–14].
PDCD4 has a nuclear localization signal (NLS) at both the N- and C-
termini, and in the central region contains two MA3 domains
homologous to the M1 domain of the protein synthesis initiation
factor eIF4G. PDCD4 inhibits the cap-dependent translation through
the binding of eIF4A at the MA3 domain, and inhibits transcription ofcertain genes through the inhibition of AP-1, a heterodimeric
transcription factor that promotes cell proliferation [12,15,16]. TGF-
β1, which is known to induce apoptosis in primary hepatocytes and
hepatocellular carcinoma (HCC) cells, increases PDCD4 expression
and PDCD4 accumulates in the nucleus during apoptosis [6]. The
ability to avoid apoptosis is one of the important cellular mechanisms
in carcinogenesis [17]. The phorbol ester,12-O-tetradecanoylphorbor-
13-acetate (TPA) is a protein kinase C (PKC) stimulator and a well-
established tumor promoter. Phorbol esters and growth factors that
stimulate PKCs are known to antagonize TGF-β1-induced apoptosis
and Smad signaling [18–20], however, the mechanisms by which TPA
suppress TGF-β1-induced apoptosis has not been fully elucidated. The
present study demonstrates that TPA reduces basal and TGF-β1-
induced PDCD4 protein expression in a PKC isoform-speciﬁc manner.2. Materials and methods
2.1. Cells and reagents
The human hepatoma cell line Huh7 was obtained from the
Japanese Cancer Research Resources Bank (Osaka, Japan). The cells
were cultured andmaintained in Dulbecco's modiﬁed Eagle's medium
(DMEM; Sigma-Aldrich, St. Louis, MO, USA) containing 10% fetal
bovine serum in 5% CO2 at 37 °C. TGF-β1 and epidermal growth factor
(EGF) were purchased from R&D systems (Minneapolis, MN, USA),
1021M. Nakashima et al. / Biochimica et Biophysica Acta 1803 (2010) 1020–102712-O-tetradecanoylphorbor-13-acetate (TPA) from Sigma-Aldrich. The
PKC inhibitors Ro-31-8425, bisindolylmaleimide-1-hydrocholoride
(Bis-1), Go6976, and rottlerin, the PI3K/Akt inhibitor LY294002, the
mTOR inhibitor rapamycin, and the proteasome inhibitor MG132 were
from Calbiochem (San Diego, CA, USA).
2.2. Cell proliferation assay
1×104 cells/well were plated onto a 24-well plate with 0.5 ml of
culture medium. TPA was added 24 h after cell placement, and 30 min
later the medium was replaced with one containing TGF-β1 at the
indicated concentration and the cells were cultured for an additional
48 h. The cells were then rinsed twice with phosphate-buffered saline
(PBS) and incubated with 0.5 ml of DMEM containing 50 μl Premix
WST-1 (Takara, Shiga, Japan) for 2 h according to the manufacturer's
protocol. The absorbance of formazan products at 450 nm was
measured with a CS-9300 microplate reader (Shimadzu, Tokyo,
Japan).
2.3. DNA ladder
Cells grown on 90 mm dishes (2×106 cells/dish) were treated
with or without TPA in the presence or absence of TGF-β1 in DMEM
containing 10% FBS for 48 h. Fragmented DNA was extracted and
separated on a 2% agarose gel as previously described [6]. DNA ladders
were visualized with Et-Br staining under UV light.
2.4. Western blotting
The protein expression of PDCD4 was investigated by Western
blotting. The cells cultured under various conditions were collected
and lysed by sonication with SDS buffer containing 50 mM Tris
(pH 6.8), 2.3% SDS and 1 mM PMSF. The cell debris was eliminated by
centrifugation at 10,000 rpm for 10 min and the supernatant was
collected. After measuring the protein concentration using a protein
assay kit (Bio-Rad, Hercules, CA), 30 or 40 μg of protein was mixed
with buffer, separated by SDS-PAGE, transferred to a polyvinylidene
diﬂuoride membrane (Bio-Rad), and blocked with 0.1% Tween and 1%
skim milk in PBS overnight. The membranes were incubated with
anti-PDCD4 antibody [6] in PBS with 0.1% Tween, 1% skim milk for 1
hour. Anti-human β-actin antibody was used as a control. The
membranes were washed ﬁve times with 0.1% Tween 20 in PBS and
stained with horseradish peroxidase-conjugated secondary antibo-
dies. All immunoblots were detected by the enhanced chemilumi-
nescence (ECL) system (Amersham, Buckinghamshire, England)
according to the manufacturer's instructions. Anti-PKCα, PKCδ, andFig. 1. TPA restored TGF-β1-induced cell growth inhibition and apoptosis in Huh7 cells. (A) TP
treatment with 0.5 or 2.0 ng/ml of TGF-β1 for 48 h. Cell growth was determined by a WST-1
from three independent experiments. (B) Huh7 cells grown on 90 mm dishes (2×106 cells/
TGF-β1 (4 ng/ml), and fragmented DNA was separated on an agarose gel under UV.PKCε antibodies were obtained from Santa-Cruz Biotechnology (Santa
Cruz, CA), anti-Akt, phopho-Akt (Ser473), S6 kinase, phosphor-S6
kinase (T389), Erk(p44/42), phosphor-Erk (Thr202/Tyr204) from
Cell Signaling Technology (Beverly, MA) and β-actin from Sigma (St.
Louis, MO). All experiments were independently repeated at least
thrice.
2.5. Real-time PCR
Total RNA of cells was extracted using ISOGEN (Nippon Gene,
Tokyo, Japan) according to themanufacturer's protocol. Real-time PCR
was performed by the TaqMan Gene Expression Assay system
(Applied Biosystems, Foster City, CA) using exons 2 and 4 of PDCD4
(No HS00205438-m1) and GAPDH (No HS99999905-m1) as a control
according to the manufacturer's protocol.
2.6. Transfection of Huh7 cells with siRNAs
siRNAs against PKCα and δ isoforms (validated siRNA AM51331)
are purchased from Ambion (Austin, TX, USA). PKCε-siRNA (HP
validated, S100587784) and Allstar negative control siRNA 1027281
were fromQiagen (Heiden, Germany). The cells were transfected with
siRNA using Lipofectamine RNAi max (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's instructions. Brieﬂy, the cells were
seeded on 35 or 60 mm dish and cultured in DMEM supplemented
with 10% FCS at 37 °C. After culturing for 2 to 3 days, the mediumwas
changed to antibiotics-free DMEM containing 10% FCS before adding
OptiMEM containing Lipofectamine and siRNAmixture and incubated
at 37 °C for 24 or 48 h.
3. Results
3.1. TPA inhibits TGF-β1-induced growth suppression and
PDCD4 expression
The effects of TPA on TGF-β1-induced growth suppression were
examined in Huh7 cells. As shown in Fig. 1A, TPA antagonized TGF-β1-
induced growth suppression in Huh7 cells, conﬁrming previous
reports [18]. In addition, the cells treated with TPA showed a
decreased DNA ladder formation (Fig. 1B). TGF-β1 induces PDCD4
expression and apoptosis in Huh7 cells [6]. Therefore, the effect of TPA
on PDCD4 expression was examined in Huh7 cells. The addition of 10,
100, 500, and 1000 nM TPA suppressed PDCD4 protein expression in a
dose-dependent fashion (Fig. 2A). TPA also inhibited PDCD4 protein
expression induced by TGF-β1 as shown in Fig. 2B.Awas added to Huh7 cell culture at the indicated concentration for 30 min, followed by
assay. The values were expressed as the ratio of OD with TPA and without TPA obtained
dish) were treated for 48 h with or without TPA (50 nM) in the presence and absence of
Fig. 2. (A) Down-regulation of PDCD4 protein level by TPA. Huh7 cells were cultured
with TPA at various concentrations of TPA for 24 h and observed by a Western blot
analysis with anti-PDCD4 antibody. (B) TGF-β1-induced PDCD4 protein expression was
suppressed by TPA. Huh7 cells were treated with 3 ng/ml of TGF-β1 for 17 h, and
thereafter the cells were treated with or without 100 nM of TPA for 3 h in a serum-free
medium and then were analyzed by Western blotting.
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PDCD4 is phosphorylated by S6K1 activated via the mitogen-
activated PI3K-Akt-mTOR signaling pathway and degraded in the
ubiquitin–proteasome system [21]. That pathway was inhibited with
the PI3K/Akt inhibitor LY294002 or the mTOR inhibitor rapamycin to
determine whether the TPA-induced PDCD4 suppression occurred
through the PI3K-Akt-mTOR signaling pathway. We previously have
observed that EFG down-regulated PDCD4 levels in inhibiting the
TGF-β1-induced apoptosis of Huh7 cells and that EGF-induced
suppression of PDCD4 was inhibited by the PI3K inhibitor LY294002
and the mTOR inhibitor rapamycin (unpublished data). Since it is wellFig. 3. PI3K and mTOR inhibitors did not reverse TPA-induced PDCD4 suppression. (A) After
for the time indicated in the ﬁgure with the serum-free DMEM containing 3 μM of LY294002
treatment. (B) After 2 h pretreatment with 0.1 nM of rapamycin or DMSO, Huh7 cells were fu
or DMSO in the presence or absence of 0.1 nM of rapamycin as indicated in ﬁgure. The cell e
Akt and S6K-phosphorylation by TPA and EGF. Huh 7 cells were incubated for 4.5 hwith a ser
(100 nM), LY294002 (3 μM) or rapamycin (0.1 nM) and then induced with DMSO as a contestablished that mitogens including EGF stimulates PI3K-Akt-mTOR
pathway [reviewed in ref. 22], we used EGF to stimulate PI3K-Akt-
mTOR pathway of Huh7 cells.
As shown in Fig. 3, neither LY294002 (Fig. 3A) nor rapamycin
(Fig. 3B) reversed the TPA-induced PDCD4 suppression, while the
inhibitors did reversed the PDCD4 suppression induced by the growth
factor EGF. The results showing involvement of the Akt–mTOR–S6K
pathway are in accordance with previous reports [13,23,24]. These
results also indicate that PKC regulates the PDCD4 levels at least
through a pathway other than the Akt–mTOR–S6K pathway. Because
the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin were
not able to reverse TPA-induced suppression of PDCD4, the phos-
phorylation of Akt and S6K was investigated to examine if TPA is able
to activate the signaling pathway. As shown in Fig. 3C, the
phosphorylation of both kinases was slightly stimulated by TPA
treatment although the stimulation was weaker than that by EGF.
Phosphorylation of Akt (p-Akt) was suppressed by the PI3K inhibitor
LY294002 and phosphorylation of S6K (p-S6K) by LY294002 and
rapamycin but not by the pan-PKC inhibitor Ro-31-8425. These results
indicate that TPA may activate the PI3K–Akt–mTOR–S6K signaling
pathway but it is minor in Huh7 cells.
3.3. PKC inhibitors increase PDCD4 expression
PKC has numerous isoforms (α, β, γ, δ, ε, η, θ, ζ, ι/τ) andα, β, δ, ε, ζ,
and ι have been variably detected in hepatoma cells [25,26]. RT-PCR
conﬁrmed that PKC isoforms including PKC α, δ, ε, ι and ζ were
expressed in Huh7 cells (data not shown). Of those expressed in Huh7
cells, PKC α, δ, and ε are activated by TPA [27] and we conﬁrmed that2 h treatment with 3 μM of LY294002, a PI3K inhibitor, Huh7 cells were further cultured
and 50 nM of TPA, 20 ng/ml of EGF or DMSO as a control. C, a control without LY204002
rther cultured for 3 h in a serum-free medium containing 50 nM of TPA, 20 ng/ml of EGF
xtracts were analyzed by Western blotting using anti-PDCD4 antibody. (C) Induction of
um-free DMEMmedium containing DMSO as a control, Ro-31-8425, a pan-PKC inhibitor
rol (D), 50 nM TPA (T) or 20 ng/ml EGF (E) incubating further for 30 min.
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shown). Huh7 cells were treatedwith several PKC inhibitors including
Bis-1 or Ro-31-8425 (pan PKC inhibitors), Go6976 (PKCα inhibitor),
and rottlerin (PKCδ inhibitor) to determine which isoforms are
involved in TPA-induced suppression of PDCD4. PDCD4 expression
was slightly enhanced in cells treated with Bis-1 prior to TGF-β1
addition, in comparison to cells treated with TGF-β1 alone (Fig. 4A),
and PDCD4 expression induced by TGF-β1 was strongly increased in
the presence of rottlerin than in its absence (Fig. 4B). While treatment
with rottlerin and Ro-31-8425 stimulated an increased expression of
PDCD4 protein, the treatment of Huh7 cells with Go6976 for 24 h did
not change the PDCD4 protein level (Fig. 4C). These results indicated
that PKCδ, but not PKCα, might therefore be involved in the TPA-
induced down-regulation of PDCD4.Fig. 5. (A) Knock-down of PKCα and PKCδ. Huh7 cells were transfected with 10 nM of
siRNA against PKCα, PKCδ or control siRNA for 24 to 48 h followed by a Western blot
analysis. (B) Knock down of PKCε. Huh7 cells were transfected with 8 or 16 nM of control
andPKCε siRNAand cultured for 24or48 h, followedbyWesternblot analysis. As a control,
DMSO (D)- and rottlerin (R) -treated cells for 24 h were indicated.3.4. Knockdown of PKC δ and ε isoforms increased PDCD4 expression
Each PKC isoform was knocked down using siRNA against PKCα, δ
and ε to conﬁrm the PKC isoform(s) involved in TPA-mediated
suppression of PDCD4. The changes in the PKC isoforms and PDCD4
protein levels were analyzed during siRNA treatment. The transfec-
tion of cells with control siRNA did not change the protein levels of
PKC isoforms and PDCD4. PKCα siRNA transfection time dependently
caused a speciﬁc decrease of PKCα protein but the PDCD4 protein
levels were not changed (Fig. 5A). PKCδ siRNA decreased the
expression of PKCδ protein, and PDCD4 protein levels were up-
regulated in association with the decrease of PKCδ protein (Fig. 5A).
Huh7 cells were transfected with siRNAs against PKCε at the different
concentrations (8 and 16 nM). PKCε siRNA decreased PKCε protein in
a dose-dependent manner and PDCD4 protein levels were increased
in association with the decrease of PKCε protein levels (Fig. 5B).Fig. 4. The effects of PKC inhibitors on PDCD4 protein levels. (A) The effects of pan-PKC
inhibitor, bisindolylmaleinmide-1-hydrochloride (Bis-1). Huh7 cells were cultured
with or without 10 μM of Bis-1 under the absence or presence of 5 ng/ml of TGF-β1 for
12 to 24 h, and then were analyzed by Western blotting for PDCD4. (B) Effects of PKCδ-
speciﬁc inhibitor, rottlerin. Cells were pre-treated with or without 10 μM rottlerin for
2 h. After the removal of rottlerin, cells were cultured with or without 5 ng/ml of TGF-
β1 for 12 to 24 h, followed by a Western blot analysis for PDCD4. (C) Effects of PKC-
inhibitors on PDCD4 protein levels. The cells were treated with 5 nM of Go6976 (PKCα
inhibitor), 10 μM of rottlerin (PKCδ inhibitor), and 100 nM of Ro-31-8425 (pan-PKC
inhibitor) for 2 h and further treated for 24 h without inhibitors, followed by aWestern
blot analysis for PDCD4.3.5. TPA, PKC inhibitor and PKC-knockdown do not change the
expression of PDCD4 mRNA
The effects of TPA and PKC inhibitors on PDCD4 mRNA levels were
examined with or without TGF-β1 stimulation of Huh7 cells. Fig. 6A
demonstrates that TGF-β1 increased the PDCD4 mRNA expression
after 24 h culture as previously shown [6]. However, TPA did not alter
the course of PDCD4 mRNA expression irrespective of the presence of
TGF-β1. As shown in Fig. 6B, the PDCD4 mRNA levels of PKC-
knockdown cells were similar to that of control cells at 24 h after
siRNA transfection when PKCδ and ε-knockdown up-regulated the
PDCD4 protein levels (Fig. 5). Similarly, PDCD4 mRNA expression was
not altered by the pan-PKC inhibitor Ro-31-8425 irrespective of the
presence of TGF-β1 (Fig. 6C), thus suggesting that PKCs were not
involved in the induction of TGF-β1-mediated PDCD4 mRNA.
3.6. The proteasome inhibitor MG132 up-regulates PDCD4 levels
PDCD4 is degraded by proteasome via E3 ubiquitin ligase β-TrCP
[21]. Huh7 cells were treated with TPA and/or MG132 to conﬁrm
whether the regulation of PDCD4 by PKC was proteasomal degrada-
tion-dependent. As shown in Fig. 7A, MG132 restored the expression
of PDCD4 protein suppressed by TPA. MG132 again restored the
PDCD4 protein levels suppressed by TPA (Fig. 7B), when cells were
treated with TGF-β1 for 17 h prior to the addition of TPA and/or
MG132, thus suggesting the involvement of PKCs in the PDCD4
degradation through a proteasomal pathway irrespective of TGF-β1.
3.7. Knockdown of PKCδ and PKCε inhibited TPA and EGF-induced
downregulation of PDCD4
Huh7 cells transfected with PKCδ and PKCε siRNA were treated
with TPA or EGF at 24 h after siRNA transfection. PKCε knockdown
increased the PDCD4 levels responding to suppression of PKCε, while
PKCδ knockdown increased the protein level with a limited level
(Fig. 8A). PDCD4 suppression by EGF was dominant and that by TPA is
less effective in PKCε knockdown cells, while only EGF but not TPA
slightly suppressed PDCD4 expression in PKCδ knockdown cells as
shown in Fig. 8A. In the PKC knockdown cells at 24 h after siRNA
treatment, phosphorylation of Akt was suppressed in PKCδ
Fig. 6. The effects of TPA, PKC inhibitor and PKC-knockdown on the PDCD4 mRNA
expression in Huh7 cells. (A) The effects of TPA on the TGF-β1-induced PDCD4 mRNA
expression. (B) The effects of PKC-knockdownon the PDCD4mRNA expression. Cells were
transfectedwith control, PKCα, δ and ε siRNAs and cultured for 24 h. (C) Theeffects of pan-
PKC inhibitor Ro-31-8425 on the expression of PDCD4 mRNA with or without TGF-β1
treatment. All data are expressed as the mean±SD of three independent experiments.
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changed in the PKCα knockdown cells compared to negative control
cells (Fig. 8B). On the TPA or EGF induction of PKC knockdown cells,
the phosphorylation of Akt and S6K was stimulated in PKCε
knockdown cells althoughEGF-inducedphosphorylationof the kinasesFig. 7. Proteasome inhibitor MG132 inhibits the TPA-induced down-regulation of
PDCD4 protein levels. (A) Huh7 cells were treated with 50 nM of TPA in the absence or
presence of 20 μM MG132 for the indicated times, followed by a Western blot analysis
for PDCD4. (B) Huh7 cells were pretreated with 5 ng/ml of TGF-β1 for 17 h and then
TPA and/or MG132 were added. After the addition of 50 nM of TPA and/or 20 μM of
MG132, the cells were then cultured for the indicated times in the ﬁgure followed by a
Western blot analysis for PDCD4.wasmore effective than TPA. Themitogen-induced phosphorylation of
the kinases was little observed in PKCα and δ knockdown cells at 24 h
after siRNA transfection (Fig. 8C). These results indicate that PKCα, δ
and ε are involved in Akt–mTOR–S6K signaling pathway although
PKCα knockdown did not affect PDCD4 protein level (Fig. 4A).
The phosphorylation of Erk was also suppressed in PKCε and δ
knockdown cells as shown in Fig. 8B. Knockdown of PKCδ inhibited
the Erk phosphorylation by TPA and EGF while inhibition of Erk
phosphorylation in PKCε knockdown cell was only slight. Knockdown
of PKCα rather increased the phosphorylation of Erk even at basal
level without stimulation of TPA or EGF (Fig. 8C).
3.8. TGF-β1 attenuates the phosphorylation of Akt and S6K in Huh7 cells
Finally, p-Akt and p-S6K levels in TGF-β1 treated cells were
investigated. As shown in Fig. 9, TGF-β1 suppressed both p-Akt and p-
S6K levels suggesting that TGF-β1 may stimulate PDCD4 expression
not only by stimulation of PDCD4 mRNA expression but also by
suppressing PDCD4 degradation through the Akt–mTOR–S6K signal-
ing pathway.
4. Discussion
TGF-β1 induces PDCD4 via the Smad-dependent pathway and
PDCD4 is one of the downstream effectors of TGF-β1 action [6]. TGF-
β1 inhibits the proliferation of the epithelial, endothelial and
hematopoietic cells and, therefore, acts as a tumor suppressor.
However, there is increased expression of TGF-β1 in many types of
cancers and the altered response to TGF-β1 is an important step in
carcinogenesis including hepatocellular carcinoma. Several factors,
such as inﬂammatory cytokines and ﬁbrotic substances modulate
TGF-β signaling and contribute to oncogenesis by modulating
inﬂammation, angiogenesis and invasion [28–31]. PDCD4 acts as a
tumor suppressor in several types of cancers and PDCD4 is down-
regulated in tumor tissues in comparison to non-tumor tissues in
these cancers [6,32–35]. Recently Sheedy et al. [36] reported that
PDCD4 regulates inﬂammatory response after LPS stimulation
suggesting the role of PDCD4 in inﬂammation-related cancers.
However, the mechanism by which PDCD4 is suppressed in tumor
cells is not fully understood.
PDCD4 protein levels are regulated by posttranscriptional and
posttranslational mechanisms. Micro RNAs (miRNAs) are endogenous
small non-coding RNAs that regulate the stability or translational
efﬁciency of target messenger RNAs and many miRNAs are aberrantly
expressed in human tumors suggesting their crucial roles in
proliferation, differentiation, and apoptosis of tumor cells. Among
these miRNAs, miR-21 plays key roles in human cancers including
liver cancer [37]. Several studies have so far identiﬁed PDCD4 as a
target of miR-21 and showed that post-transcriptional down-
regulation of PDCD4 by miR-21 stimulated transformation, invasion
and metastasis [38–40].
The stimulation of cells by growth factors leads to the degradation
of PDCD4 protein through phosphorylation of the Ser67 by S6 kinase 1
(S6K1) via the PI3K/Akt/mTOR pathway and ubiquitination by SCF
βTRCP ubiquitin ligase [21]. Schmid et al. [13] reported that TPA
enhances PDCD4 degradation via activation of the PI3K/Akt/mTOR
andMEK signaling pathways. TPA is a potent simulator of PKC and has
also been shown to antagonize TGF-β1-induced growth suppression
of cells [18]. However, it is not knownwhether the speciﬁc isoforms of
PKCs are involved in TPA-mediated regulation of PDCD4 protein. The
present study showed that TPA decreased the tumor suppressor
PDCD4 protein in a PKC isoform-speciﬁc manner. PKC plays important
roles in the various aspects of signal transduction pathways that
regulate cell proliferation, differentiation, transformation and apo-
ptosis [41]. PKC isoforms are divided into the conventional (cPKCs: α,
βI, βII, and γ), novel (nPKCs: δ, ε, η, and θ) and atypical (aPKCs: ζ and
Fig. 8. Phosphorylation levels of Akt, S6K and Erk in PKC knockdown cells. Huh 7 cells were transfected with 8 nM PKCα, δ and ε siRNA and cultured for 24 h. (A) TPA and EGF-
induced suppression of PDCD4 in PKC-knockdown cells. Huh 7 cells transfected with PKCδ, PKCε and negative control (nC) siRNA were induced with 50 nM of TPA (T), 20 ng/ml of
EGF (E) and DMSO as a control (D) in a serum-free DMEM. Cells were examined byWestern blotting at 3 h after treatment with mitogen. In the EGF induction same amount of DMSO
as the control was added. (B) Phosphorylation levels of Akt, S6K and Erk in PKC-knockdown cells. Huh 7 cells were transfected with siRNA of negative control (nC), PKCα, PKCδ, PKCε
and both PKCδ and ε, and examined byWestern blotting at 24 h after siRNA transfection. (C) Induction of Akt-, S6K- and Erk-phosphorylation by TPA and EGF. Huh 7 cells transfected
with siRNA of negative control (nC), PKCδ, PKCε (left panel) and PKCα (right panel) were treated for 30 min with 50 nM of TPA (T), 20 ng/ml of EGF (E) and DMSO as a control (D) in
a serum-free DMEM, and examined with Western blotting. In the EGF induction same amount of DMSO as the control was added.
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[42]. Each PKC isoform shows a tissue-speciﬁc expression pattern and
speciﬁc subcellular localization and is thought to play speciﬁc roles
[43,44]. PKCα, PKCε and PKCδ are dominantly expressed in liverFig. 9. TGF-β1 suppresses phosphorylation of Akt and S6K. Huh 7 cells were cultured for
24 h in the presence and absence of TGF-β1 (4 ng/ml) and analyzed byWestern blotting.cancer cell lines but expression of PKCβ, PKCγ, PKCη and PKCθ are not.
PKCα, a conventional PKC, is overexpressed in some cases of HCC and
involved in the development, proliferation and invasion of HCC cells
[45–47]. Although the expression of novel PKCs in the liver cancerwas
reported, the role of the novel PKCs, PKCδ and PKCε in liver cancer
remains unclear. PKCδ and PKCε play differential roles in the
development and progression of cancer by regulating proliferation,
invasion and apoptosis [48]. The current data showed that knockdown
of PKCδ or PKCε by siRNA reversed the PDCD4 protein levels after TPA
exposure to HCC cells, thus suggesting the requirement of novel PKCs
in the down-regulation of PDCD4, most probably via proteasomal
degradation. Recent reports have demonstrated the activation of the
PI3K/Akt/mTOR pathway to be required to induce the proteasomal
degradation of PDCD4. However, the presence of pathways that
promote PDCD4 protein degradation other than the PI3K/Akt/mTOR
pathway has also suggested [13].
We have observed that the PI3K inhibitor LY294002 and mTOR
inhibitor rapamycin are not able to reverse the TPA-induced PDCD4
1026 M. Nakashima et al. / Biochimica et Biophysica Acta 1803 (2010) 1020–1027suppression in Huh7 cells in contrast to the results in which LY294002
reversed the TPA-induced PDCD4 suppression in HEK293 cells [13].
Although the pathway other than the PI3K/Akt/mTOR seems to be
dominant for the TPA-induced PDCD4 suppression in Huh7 cells, the
analyses of phospho-Akt and phospho-S6K indicate that the PI3K–
Akt–mTOR–S6K signaling cascade also contributes at least partly in
the TPA-induced PDCD4 degradation (Fig. 3C, Fig. 8) in accordance
with previous reports [13,23,24]. It is also possible that the pathway
other than the PI3K/Akt/mTOR is accelerated by TPA under the
presence of TGF-β1 because the phosphorylation of Akt and S6K has
been suppressed in TGF-β1-treated Huh7 cells (Fig. 9). Phosphoryla-
tion of Erk is stimulated at similar levels by TPA as well as by EGF and
is suppressed in the presence of siRNA against PKCδ and ε (Fig. 8B).
The suppression of TPA- or EGF-induced Erk phosphorylation by PKCε
knockdown was slightly compared to that by PKCδ knockdown
(Fig. 8C), suggesting the differential role of PKCδ and ε in the Erk
phosphorylation by mitogens. The data also showed the partial
association between PDCD4 suppression and Erk phosphorylation,
indicating the involvement of Erk signal in the regulation of PDCD4 as
recently reported [13]. PDCD4 has a number of putative phosphor-
ylation sites for many types of kinases [10]. It is also possible to
speculate that direct phosphorylation of PDCD4 by kinases, such as
members of the MAP kinase pathway and PKC family might lead to
proteasomal degradation, although this hypothesis requires further
study.
In conclusion, the current study revealed that the tumor
suppressor PDCD4 is regulated in a PKC isoform-speciﬁc manner.
The results showed the involvement of the novel PKC isoforms, PKCδ
and PKCε, in the degradation of PDCD4 protein through proteasomes.
As a result, the inhibition of PDCD4 degradation through PKC
inhibition might therefore provide a novel strategy for cancer
prevention and/or cancer treatment.
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